Drug Trial Radar · NCT07459166
A Phase 2 Safety, Tolerability, PK, and Efficacy Study of CS-1103 Following Fentanyl Challenge With Naloxone Blockade
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
May 28, 2026
Primary completion
Jul 15, 2026
Study completion Jul 22, 2026
Sponsor
- Lead sponsor
- Clear Scientific, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- National Institute on Drug Abuse (NIDA)
- First posted
- Mar 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of CS-1103 (1,000 mg), given by intravenous (IV) infusion in healthy participants in the presence of a clinically relevant dose of fentanyl (200 μg, IV), with naloxone blockade (400 μg, IV).
Conditions
- Fentanyl Overdose
- Fentanyl Poisoning
Interventions
Naloxone HydrochlorideDrug
Naloxone for intravenous administration
FentanylDrug
Fentanyl for intravenous administration
Sterile SalineDrug
Sterile Saline for intravenous administration
CS-1103Drug
CS-1103 for intravenous administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with CS-1103-related adverse events (AEs) assessed by physical examinationsTime frame: 3 days plus follow-up on Day 10
- Number of participants with CS-1103-related adverse events (AEs) assessed by electrocardiograms (ECGs)Time frame: 3 days plus follow-up on Day 10
- Number of participants with CS-1103-related adverse events (AEs) assessed by vital signsTime frame: 3 days plus follow-up on Day 10
- Number of participants with CS-1103-related adverse events (AEs) assessed by laboratory parametersTime frame: 3 days plus follow-up on Day 10
- Time course of CS-1103 blood and urine concentrationsTime frame: 48 hours
- Time course and magnitude of urine excretion of fentanylTime frame: 48 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
California Clinical Trials Medical Group
Glendale, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.